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Abstract Migraine is a highly
prevalent and disabling disease
that is substantially undiagnosed in
primary care. Recently, the ID
Migraine, a self-administered ques-
tionnaire, was shown to be a valid
and reliable screener for migraine
in primary care in the USA. To
validate an Italian version of the
ID Migraine, we planned a multi-
centric study, evaluating at least
220 patients affected by various
form of headache. The responses to
the questionnaire were compared
with the diagnosis of headache
made by a headache specialist
blind to the result of the question-
naire. Sensitivity, specificity, and
positive and negative predictive
values for migraine were calculat-
ed. The statistical analysis on 140
patients now examined showed a
very good performance of the ID
Migraine with high sensitivity:
0.94 (95% CI: 0.89–0.95), speci-
ficity: 0.70 (95% CI: 0.54–0.86)
and positive predictive value: 0.89
(0.82–0.95). If confirmed, these
results would establish ID
Migraine as a valid screening
instrument for migraine in Italian
headache patients and warrant fur-
ther investigation in primary care
to assess the validity of this ID
screener in Italian population.
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Introduction
Although migraine represents an important cause of tem-
porary disability [1, 2], as shown by recent surveys, about
50% of persons with migraine, even those with disabling
headache, have never consulted a physician for the prob-
lem [3]. Moreover, only one third of migraine sufferers
are currently treated with a prescription drug [4]. The low
rates of diagnosis and treatment have several causes,
including low medical consultation specifically for
headache. Improving recognition of migraine in primary
care will increase the rate of successful treatment with
effective migraine-specific therapies. Recently, Lipton et
al. validated a very brief self-administered questionnaire,
consisting of only 3 items, the ID Migraine, for screening
of migraine headache in primary care practice (PCP) [5].
ID Migraine was found to be a very good tool for recog-
nition of migraine sufferers, showing very high sensitivi-
ty, specificity and positive predictive value (PPV) for
migraine headache in a primary care setting.
The aim of the present study was to validate an Italian
version of ID Migraine, to be used for migraine screening
in Italian headache patients.
Subjects and methods
We planned a multicentric study involving several headache cen-
tres to evaluate at least 220 consecutive patients affected by var-
ious forms of headache. The size of the sample to be examined
was determined taking into account the prevalence of migraine
headaches.
Consecutive headache patients aged 18–65 years referring to
the headache centres involved in the study and reporting at least
two headaches in the last three months were eligible for the
study; according to the inclusion criteria used by Lipton et al.
[5], patients had also to indicate that they had experienced at
least a headache that interfered with their lives. Each patient
completed an Italian version of the ID Migraine (Fig. 1), previ-
ously translated by Pfizer, which also has the copyright of the
original ID Migraine. Pfizer authorised the authors to use the
Italian version of the ID questionnaire for screening of migraine
in an Italian headache population.
Patients gave their informed consent to participate in the
study, which was approved by the local ethics committee.
According to Lipton et al. [5], the response to each item was
treated as a binary variable with a “no” assigned to responses of
“never” or “rarely” and “yes” assigned to responses of “less than
half the time” or “half the time or more.”
After completing the questionnaire, patients were evaluated
by a board-qualified headache specialist blind to the result of the
ID Migraine. He performed a complete clinical evaluation
including medical history, physical examination, comprehensive
neurologic history and examination (including additional diag-
nostic tests if clinically indicated), and made headache diagnosis
according to the criteria of the new classification of the
International Headache Society (IHS), which was considered the
gold standard [6].
The responses to the items of the questionnaire were then
compared with the diagnosis and the validity was assessed cal-
culating sensitivity, specificity, positive (PPV) and negative
(NPV) predictive values. Test-retest reliability was evaluated in
an independent sample of 20 patients that repeated the question-
naire 2–5 days after, through Kappa coefficient for intraclass
correlation.
Results
We have now evaluated 140 patients (F/M: 98/42, mean
age: 38±12.7) affected by various forms of headache,
about 60% of the sample to be examined. Seventy per cent
of them (98 patients; F/M: 71/27; mean age: 36.7±11.8)
were affected by migraine and the remaining 30% (42
patients; F/M: 28/14; mean age: 36.7±11.8) by non-
migraine headache. In this last group 67% had tensive,
10% cluster and 23% other headaches. Table 1 shows sen-
sitivity, specificity, positive (PPV) and negative (NPV)
predictive values of positive responses to the ID items for
the diagnosis of migraine.
Analysis of the single questions showed high values
of sensitivity and PPVs for each item (>80%), disability
reaching the highest score in sensitivity 0.98
(0.96–1.01); and photophobia the highest PPV: 0.89
(0.82–0.96). Specificity had generally lower scores;
lower scores were observed also in NPV for all items
Questionario ID Migraine:
Durante gli ultimi tre mesi ha avuto i seguenti disturbi contemporaneamente al mal di testa?
1. Ha avuto nausea o conati di vomito? sì no
2. Le ha dato fastidio la  luce 
2. (molto di più di quando non ha mal di testa)? sì no
3. Il mal di testa ha limitato, per almeno un giorno
3. la sua capacita di lavorare,  studiare o fare quello che deve? sì no
Fig. 1 Italian version of the ID Migraine
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except disability, which showed the highest NPV value:
0.95 (0.85–1.5). Empirical combinations of the three
items of the ID questionnaire found that positive
response on any two out of the three items gave an opti-
mal score with sensitivity of 0.94 (95% CI: 0.89–0.95),
specificity of 0.70 (95% CI: 0.54–0.86), PPV of 0.89
(0.82–0.95) and NPV of 0.83 (0.70–0.96). In the subjects
that took the questionnaire twice, test-restest reliability
was good (Kappa coefficient: 0.70).
Discussion
This study reports results on about 60% of the sample we
planned to examine to evaluate the validity of an Italian
version of the ID Migraine. Even though preliminary,
validity and reliability measures show that the three-item
ID Migraine Screener appears to be a valid and reliable
screening instrument for migraine headaches also in
Italian headache patients. Indeed it had sensitivity of 0.94
(95% CI: 0.89–0.95), specificity of 0.70 (95% CI:
0.54–0.86), PPV of 0.89 (0.82–0.95) and NPV of 0.83
(0.70–0.96) for the diagnosis of migraine headaches.
These scores indicate an overall good validity level of the
Italian version of the ID questionnaire and are also in
good agreement with the results by Lipton et al. [5], which
found sensitivity of 0.81 (95% CI, 0.77–0.85), specificity
of 0.75 (95% CI, 0.64–0.84) and PPV of 0.93 (95% CI,
89.9–95.8) of the ID Migraine screener in a primary care
setting in the USA. Compared to this study, in our sample
we had higher sensitivity and lower specificity scores.
These differences however are slight and not relevant as
concerns the validity of the Italian as compared to the
English version of the ID Migraine. Moreover, the repeti-
tion of the Italian version of the ID Migraine in an inde-
pendent sample of 20 patients showed a good test-retest
reliability with a Kappa coefficient of 0.70, which is very
similar to the value of 0.68 found by Lipton et al. [5].
We used ID Migraine in headache centres, a setting in
which a different, higher rate and severity of migraine
headache could be expected with respect to PCP. This
could have affected measures like NPV and PPV that are
critically dependent on the prevalence of the disorder in
the sample. Because of these limitations, the validity of
our results should be confined, at least as concerns NPV
and PPV measures, to the patient population of tertiary
headache centres. However, the percentage of migraineurs
in our sample (70%) is similar to that reported by Lipton
et al., who found 332 patients affected by migraine on a
total validation sample of 443 patients screened (75%).
This high prevalence could be due to the following inclu-
sion criteria used by Lipton et al. to favour identification
of migraineurs in PCP attendees complaining of headache:
two headaches in the previous 3 months and a disabling
headache in the past.
In conclusion, preliminary observations on 60% of the
sample we planned to examine showed the Italian version
of the ID Migraine as a valid and reliable tool for screen-
ing of migraine in Italian headache patients. If confirmed
in the total sample, these results would warrant further
validation of the ID Migraine screener in PCP. This indeed
would establish the Italian ID Migraine as a simple and
effective tool to increase recognition of migraineurs also
in an Italian population, giving these patients the chance
of more specific and effective treatment.
Table 1 Validity scores of single and combination of two out of the three items of the ID Migraine
Sensitivity (CI 95%) Specificity (CI 95%) PPV (CI 95%) NPV (CI 95%)
Nausea 0.85 (0.78–0.92) 0.64 (0.47–0.79) 0.86 (0.79–0.93) 0.62 (0.46–0.78)
Photophobia 0.77 (0.68–0.86) 0.76 (0.59–0.93) 0.89 (0.82–0.96) 0.56 (0.41–0.71)
Disability 0.98 (0.96–1.01) 0.52 (0.34–0.68) 0.84 (0.77–0.91) 0.95 0(0.85–1.5)
2 Items positive 0.94 (0.89–0.98) 0.70 (0.54–0.86) 0.89 (0.82–0.95) 0.83 (0.70–0.96)
PPV, positive predictive value; NPV, negative predictive value
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